Division of Experimental Hematology and Cancer Biology
Elisa Boscolo is an Assistant Professor in the Division of Experimental Hematology and Cancer Biology, at the Cincinnati Children’s Hospital Medical Center, Ohio. She received her undergraduate degree in Molecular Biology and PhD in Tissue Engineering from the University of Padova, Italy.
Dr. Boscolo completed her post-doctoral fellowship in the Vascular Biology Program at the Boston Children’s Hospital, Harvard Medical School, in the laboratory of Dr. Joyce Bischoff. Her studies on infantile hemangioma, a vascular tumor, led to the identification of a population of stem cells capable of forming hemangioma-like blood vessels when injected in mouse. This model has been a fundamental tool to investigate the efficacy of new drug treatments, and to elucidate the cellular and molecular targets of corticosteroids and propranolol, past and current treatments for this tumor. In 2010 Dr. Boscolo was promoted to Instructor and few years later was awarded an R01 from the NIH to generate a TIE2-related murine model of venous malformation.
In 2014, Dr. Boscolo was recruited to Cincinnati Children’s Hospital. Her laboratory focuses on modeling vascular anomalies in mouse with the use of patient-derived cells or with transgenic animal systems that mimic genetic defects found in patients. The goal of her research program is to identify genes and signaling pathways crucial for the formation of vascular anomalies as these discoveries can have the greatest impact on the understanding of processes regulating normal and pathological blood vessel formation.
Rapamycin improves TIE2-mutated venous malformation in murine model and human subjects.
The Journal of clinical investigation Sep, 2015 | Pubmed ID: 26258417
EGFL6 Regulates the Asymmetric Division, Maintenance, and Metastasis of ALDH+ Ovarian Cancer Cells.
Cancer research 11, 2016 | Pubmed ID: 27803106
A xenograft model for venous malformation.
Angiogenesis 11, 2018 | Pubmed ID: 29786783
Combined mTOR and MEK inhibition is an effective therapy in a novel mouse model for angiosarcoma.
Oncotarget May, 2018 | Pubmed ID: 29872503
Ponatinib Combined With Rapamycin Causes Regression of Murine Venous Malformation.
Arteriosclerosis, thrombosis, and vascular biology 03, 2019 | Pubmed ID: 30626204
RUNX represses to drive neurofibromagenesis.
Science advances 04, 2019 | Pubmed ID: 31032403
Constitutive Active Mutant TIE2 Induces Enlarged Vascular Lumen Formation with Loss of Apico-basal Polarity and Pericyte Recruitment.
Scientific reports 08, 2019 | Pubmed ID: 31451744
Constitutively active PIK3CA mutations are expressed by lymphatic and vascular endothelial cells in capillary lymphatic venous malformation.
Angiogenesis Apr, 2020 | Pubmed ID: 32350708
关于 JoVE
版权所属 © 2024 MyJoVE 公司版权所有,本公司不涉及任何医疗业务和医疗服务。